Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002041 | 0.84 | EPHX1 (0.42) | EPHX1 | |
| SCHEMBL7020097 | 0.79 | F2 (0.39) | F2PRSS1PRSS2PRSS3EPHX1 | |
| SCHEMBL17226211 | 0.70 | F2 (0.32) | F2PRSS1PRSS2PRSS3EPHX1 | |
| SCHEMBL17226210 | 0.68 | F2 (0.34) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL17226207 | 0.67 | EPHX1 (0.36) | F2PRSS1PRSS2PRSS3EPHX1 | |
| SCHEMBL736692 | 0.67 | — | — | |
| SCHEMBL1362233 | 0.67 | — | — | |
| SCHEMBL2016323 | 0.65 | — | — | |
| SCHEMBL4483429 | 0.65 | — | — | |
| SCHEMBL7121562 | 0.65 | GAA (0.40) | F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| EP-0665843-B1 | SUBSTITUTED QUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6194436-B1 | THERAPY FOR LUNG CANCER | PFIZER INC. | 2001-02-27 | — | — | US | disclosed |
| US-5990125-A | NK-1 receptor antagonists for the treatment of cancer | PFIZER INC. (US) | 1999-11-23 | — | — | US | disclosed |
| US-5837711-A | Substituted quinuclidines as substance P antagonists | PFIZER INC. (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0773026-A2 | NK-1 receptor antagonists for the treatment of cancer | PFIZER INC. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5569662-A | ANTIINFLAMMATORY AGENT, GASTROINTESTINAL DISORDERS, NERVOUS SYSTEM DISORDERS, ANTIASTHMA AGENTS, ANALGESICS | PFIZER INC. (US) | 1996-10-29 | — | — | US | disclosed |
| EP-0665843-A1 | SUBSTITUTED QUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0632809-A1 | QUINUCLIDINE DERIVATIVES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1995-01-11 | — | — | EP | disclosed |
| WO-1994010170-A1 | SUBSTITUTED QUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1993019064-A1 | QUINUCLIDINE DERIVATIVES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1993-09-30 | — | — | WO | disclosed |